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Transgenic miceHere we address the assumption that the massive intact albuminuria accompanying mutations of
structural components of the slit diaphragm is due to changes in glomerular permeability. The
increase in intact albumin excretion rate in Cd2ap knockout mice by >100-fold was not accompa-
nied by equivalent changes in urine ﬂow rate, glomerular ﬁltration rate or increases in dextran
plasma clearance rate, which demonstrates that changes in glomerular permeability alone could
not account for the increase in intact albumin excretion. The albuminuria could be accounted for
by inhibition of the tubule degradation pathway associated with degrading ﬁltered albumin. There
are remarkable similarities between these results and all types of podocytopathies in acquired and
toxin-induced renal disease, and nephrotic states seen in mice with podocyte mutations.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The mechanism of albuminuria (excess albumin in the urine), a
hallmark of kidney disease, is currently subject to considerable
controversy. Albuminuria is particularly massive when there is a
genetic change leading to defects in structural components of the
slit diaphragm associated with podocytes of the glomerulus.
Mutations in the nephrin gene, which encodes nephrin, a critical
component of the slit diaphragm, are the major cause of congenital
nephrotic syndrome and its associated albuminuria in humans [1].
Similarly CD2AP (CD2 associated protein-scaffolding molecule that
regulates the actin cytoskeleton) is also expressed in the slit
diaphragm; Cd2ap knockout mice (Cd2ap/) exhibit congenital
nephrotic syndrome [2,3], and humans with CD2AP mutations
exhibit focal glomerulosclerosis [4]. The underlying assumption,
that has yet to be proven, has been that genetically altering
glomerular function would structurally allow large quantities of
albumin to leak into the primary urine space. As it is difﬁcult to
perform urinary clearance studies in transgenic mice, since the
mice are unwell with low urine volumes, we instead examined
the plasma elimination of albumin and dextran mot wt 70000 in
both Cd2ap/ and wild type mice (Cd2ap+/+). Previous studies haveshown that in nephrotic states in rats, the increase in plasma
elimination of albumin of >260% totally accounts for the increase
in urinary excretion of albumin [5–7]. Therefore, changes in the
plasma elimination of albumin in Cd2ap/ mice should reﬂect
the nephrotic state whereas changes in dextran plasma clearance
should reﬂect changes in glomerular permselectivity.
2. Materials and methods
All animal experiments were approved by the Institutional
Committee on Research Animal Care, in accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animal Guidelines, and protocols established by the
Institutional Animal Care and Use Committee were strictly
followed. B6 mice were used. The knockout mice have Cd2ap
ubiquitously deleted in all cells and the deletion strategy has been
described [3]. An equal distribution of male and female mice was
used for both Cd2ap+/+ and Cd2ap/ mice.
The mice were weighed and pre bled anywhere from 24 h to1 h
prior to injections of labeled material, and the plasma prepared and
stored at 20 C. On day 0, 70 kD ﬂuorescent dextran (50 ll FITC-
dextran plus 50 ll 0.9% saline) was injected into the tail vein using
insulin syringes and the animals were then placed in metabolic
cages for 24 h. At 15 min, 3 h and 24 h post injection, the animals
were bled (50 ll) and plasma collected. At 24 h post-injection
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Fig. 1. Urine (1A) and plasma (1B) from a set of three Cd2ap/ mice (lanes 4 to 6)
and three Cd2ap+/+ mice (lanes 1 to 3) separated by electrophoresis on a 4–12%
gradient polyacrylamide gel and stained with Coomassie Brilliant Blue. Similar
proﬁles were obtained with urine from either male or female mice.
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shielded from light), weighed, and stored at 20 C. The FITC dex-
tran was cleared from the plasma within the ﬁrst 24 h. On day 2
the mice were weighed and then injected in the tail vein with
Alexa 488-labelled albumin (40 ll Alexa 488 albumin plus 40 ll
0.9% saline) using insulin syringes, and as before the mice placed
in metabolic cages. At 15 min, 3 h and 24 h post-injection the ani-
mals were bled and plasma collected and stored at 20 C. At 24 h
post-injection the urine was collected from the metabolic cages,
weighed and stored at 20 C. Urine collection in metabolic cages
is subject to some loss. We assume that tail vein injections and
blood collections had no effect on kidney function, as urine creat-
inine excretion and urine volume ﬂow were the same for collec-
tions for days 0 to 1 and days 2 to 3. Urine collected on day 0
and day 2 were assayed for creatinine (Mouse Creatinine Assay
Kit, Crystal Chem, IL). Day 2 urine was also fractionated on PD-10
columns (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Both
plasma and urine samples were analysed by electrophoresis on
on 4–12% gradient polyacrylamide gels (Invitrogen, Grand Island,
New York).
A total of 16 mice was studied, 8 Cd2ap+/+ and 8 Cd2ap/. All
were used to examine dextran and albumin plasma clearance.
Three of each were used to examine total albumin clearance and
creatinine excretion (Table 1).
Mouse serum albumin (Fraction V; Sigma–Aldrich) was
conjugated to Alexa 488 (Molecular Probes, Carlsbad, CA) accord-
ing to the manufacturer’s instructions for amine-reactive probes
as previously reported [8]. FITC-dextran had a number average
molecular weight of 45,500 and a weight average molecular weight
of 69,700, and an average radius of 5.3–6.5 nm (gift from Pharma-
cia, Uppsala, Sweden). It is the same preparation that was used in
2-photon studies measuring its glomerular sieving coefﬁcient
(same as albumin [8]) in healthy control rats and in streptozotocin
diabetic rats [8].
Statistics were measured by a two-tailed t test. Data are pre-
sented as means ± S.D.
3. Results
The baseline parameters of urine ﬂow rate and glomerular
ﬁltration rate (GFR) (as reﬂected in urine creatinine) were essen-
tially identical for both Cd2ap+/+ and Cd2ap/mice (Table 1). There
may be a trend to decreasing GFR with the Cd2ap/ mice, but the
difference was not signiﬁcant. There was a moderate increase
(3-fold increase) in the urinary excretion rate of albumin-derived
ﬂuorescence in the Cd2ap/ mice.
Gel electrophoresis with Coomassie Brilliant Blue stain revealed
a major albumin band in the urine of Cd2ap/ mice together
(Fig. 1A) with a range of higher molecular weight proteins that
were clearly not present in the urine of the Cd2ap+/+ mice. Dilution
of the urine by 30-fold still demonstrated a signiﬁcant albumin
band (not shown), which would indicate that the Cd2ap/ mice
exhibited a >100-fold increase in intact albumin excretion rate as
compared to Cd2ap+/+ mice. This albuminuria was accompanied
by hypoalbuminemia (Fig. 1B). Conversely, there appeared to beTable 1
Physiological characteristics of 5 week-old Cd2ap mutant and control mice.
Weight (g)
Urine ﬂow rate (ml/24 h)
Urine creatinine excretion rate* (lg/24 h)
Excretion rate of albumin-derived ﬂuorescence (ﬂuorescence units/24 h)
* Urine creatinine was measured in samples taken on day 0 and day 2.
 p = 0.02.hyperproteinemia for proteins with molecular weights >100000
in the plasma of Cd2ap/ mice.
Plasma elimination of Alexa 488-labelled albumin and FITC-
dextran (mol wt 70000) is shown in Fig. 2. Instead of the plasma
elimination of albumin and dextran increasing in the albuminuric
Cd2ap/ mice, they actually signiﬁcantly decreased. Given that
urine ﬂow rate and urine creatinine is not signiﬁcantly altered in
Cd2ap/,mice, and that the increase in excretion of
albumin-derived material is only moderate in these mice, then it
is apparent that changes in glomerular permeability cannot be di-
rectly responsible for the massive change in intact albuminuria
(>100-fold) seen in Cd2ap/ mice.
In terms of mechanism, the > 100-fold increase in intact albu-
minuria in urine (Fig. 1A) appears to arise from the change in the
integrity of urinary albumin. Fig. 3 demonstrates that Cd2ap+/+
mice excrete small quantities of intact albumin but relatively large
quantities of heavily degraded albumin. On the other hand
Cd2ap/ mice excrete essentially intact albumin only.
4. Discussion
There are two disparate concepts for the mechanism of albu-
minuria. There is the traditional glomerular model [9], whichCd2ap+/+ (n = 3) Cd2ap/ (n = 3)
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Fig. 2. Plasma elimination of FITC-dextran (n = 8, p = 0.006, Cd2ap+/+ vs Cd2ap/)
and Alexa 488-albumin (n = 8, p = 0.03, Cd2ap+/+ vs Cd2ap/) measured at 3 h
relative to 15 min after iv injection.
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Fig. 3. Fractionation of Alexa 488-albumin-derived material in urine collected on
day 2. The darker symbols represents material from Cd2ap/mice. The later eluting
material (6–11 ml) in this proﬁle for the Cd2ap/ mice is autoﬂuorescence not
derived from Alexa 488-albumin, as seen in urine proﬁles for both Cd2ap+/+ and
Cd2ap/ without the presence exogenous ﬂuorescent labeled material.
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ma albumin and it is only when there are structural changes to the
ﬁlter that albumin is able to leak through giving rise to the
albuminuric condition. The alternative more recent view is that
albuminuria is based on post-ﬁltration proximal tubular process-
ing of ﬁltered albumin [10]. This mechanism states that the glo-
merular ﬁlter leaks albumin (glomerular sieving coefﬁcient is
0.03 as compared to conventional view of 0.0006 [10]) as it is ﬁl-
tered on the basis of size alone. Most of the ﬁltered albumin
(>95%) is retrieved by the proximal tubule and returned to the
blood supply intact, whereas that material not retrieved is de-
graded, with the peptides exocytosed to the urinary space and ex-
creted [10]. Inhibition of the retrieval pathway will result in net
amounts of albumin lost from the circulation giving rise to hypoal-
buminemia. Inhibition of the degradation pathway will simply al-
ter the integrity of the albumin being excreted and therefore itsdetection, as commonly used immunoassays only detect intact
albumin and not albumin peptides. Previous studies have shown
that in nephrotic states in rats the increase in urinary excretion
of intact albumin is 2 to 3 orders of magnitude higher (inhibition
of the degradation pathway) and 10-fold for albumin-derived
material (inhibition of the retrieval pathway) without any major
change in glomerular permeability [11].
The appearance of albumin peptides in the urine of Cd2ap+/+
mice is in agreement with many studies showing that ﬁltered albu-
min undergoes extensive degradation in the kidney prior to uri-
nary excretion, as demonstrated in vivo [11–15], in isolated
perfused kidneys [12,16], and in proximal tubule cells [17–18].
The degradation appears to be lysosomal-based [12,19] and is
quantitatively similar to that by which albumin is processed by
the megalin–cubilin pathway [10,20]. Inhibition of the degradation
pathway has been associated with decreased tubular lysosomal
activity [14,15,21–23]. In vivo excretion of non-renal derived albu-
min peptides was viewed to be insigniﬁcant due the use of very
high levels of tritium labelled albumin (2  106 dpm bolus iv)
which do not produce any circulating peptides measured at a sen-
sitivity of 0.003% [13]. Similar experiments with non-ﬁltering kid-
neys produced the same result [11]. Yet, in a recent publication by
Weyer et al. [24], opposite conclusions were reached where it was
claimed that albumin peptides found in urine are primarily the re-
sult of the excretion of non-renal degradation products well be-
yond the capacity of the megalin/cubilin receptor in the proximal
tubule. The conclusions were solely based on the appearance of
radiolabelled high molecular weight and low molecular weight
material in urine and plasma of iv-injected 125I-labelled mouse
albumin. The results obtained were markedly different from those
published by Comper et al. [10–13]; (i) the amount of 125I-labelled
low molecular weight material seen by Weyer et al. [24] in the
plasma was 1% of the labelled material, whereas in studies by
Osicka and Comper [13] the plasma analysed contained 30 times
more radiolabelled albumin and no low molecular weight material
could be detected (sensitivity down to at least 0.003%) (ii) the rate
of appearance of 125I-labelled material in the urine in the study
Weyer et al. [24] was extraordinarily high, at 8% of the injected
dose in 6 h. This would mean that the mice would excrete approx-
imately a third of their plasma albumin in a day and be unrealisti-
cally nephrotic [25]. The results of Weyer et al. [24] can very
plausibly be explained by assuming that part of their 125I-labelled
albumin was denatured during labelling [26], as denatured mate-
rial is known to be rapidly cleared from the plasma [26–28] and
does not represent the physiological processing of unlabelled or
non-denatured albumin.
With Cd2ap/ mice there is clear inhibition of the degradation
pathway, with all the albumin excreted in intact form and with
very low quantities of albumin peptides. The appearance of a range
of other intact proteins in the urine of Cd2ap/ mice (Fig. 1A) is
also evidence of the inhibition of the degradation pathway, as it
is known to operate on all ﬁltered proteins [11,29].
We have noted in this study that Cd2ap/ mice exhibited rela-
tively small changes in the plasma elimination of dextran and albu-
min, urinary excretion of albumin-derived material and creatinine,
but none of these compare to the massive change in intact albu-
minuria. The clear phenotype for Cd2ap/mice is a glomerular de-
fect [2], but we cannot eliminate subtle effects on capillary-tissue
exchange governing plasma elimination of dextran and albumin.
However, this will not account for the >100-fold increase in intact
albuminuria. In terms of dextran clearance, we have noted that
both Cd2ap+/+ and Cd2ap/mice clear dextran from the circulation
in less than 24 h. The behaviour of the plasma clearance of albumin
relative to dextran was unexpected for nephrotic states associated
with massive proteinuria and hypoalbuminemia. While there was
some convergence of the plasma elimination rate of albumin to
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gest that part of the cause of hypoalbuminemia was a small change
in glomerular permeability with subsequent overloading of the
retrieval pathway [30]. This could be combined with partial
inhibition of the retrieval pathway that will paradoxically (cf. the
massive changes in intact albuminuria due to inhibition of the deg-
radation pathway) lead to hypoalbuminemia.
There is a remarkable similarity of the results seen in this study
with those seen in a wide range of podocytopathies associated
with acquired and toxin-induced albuminuria [10,31]. In all of
these, including focal glomerulosclerosis [31], there are 2 to 4
orders of magnitude change in intact albuminuria, without any
major change in glomerular permeability as studied with well
characterised transport probes. Intact albuminuria, due to inhibi-
tion of the degradation pathway, is the only mechanism to account
for the major changes that are observed as speciﬁcally shown in
puromycin aminonucleoside nephrosis and antiGBM disease [11].
In view of the lack of major changes in glomerular permeability,
inhibition of the degradation pathway is also likely to explain in-
tact albuminuria in all types of transgenic mice exhibiting nephro-
sis, such as the intact albumin excretion seen upon podocin
inactivation [32], which is similar to that in Cd2ap knockout mice.
The mechanism by which the degradation pathway is inhibited is
not known. It would be consistent with the involvement of Cd2ap
in endosomal trafﬁcking [33]. However in view of the generality
of the results it appears that perturbing the structural environment
of podocytes creates factors that are released from the podocyte
that subsequently inﬂuence the degradation pathway
downstream.
Acknowledgements
L.M.R. and W.D.C. acknowledge support from Exosome
Diagnostics Inc. LMR was funded by JDRF grants 10-2006-75 and
5-2008-722 and acknowledges the MGH Program in Membrane
Biology. A.S.S. acknowledges support from Howard Hughes
Medical Institute and NIDDK.
Preliminary parts of this work were presented as posters at the
2010 and 2012 Annual meeting of the American Society of
Nephrology.
References
[1] Kestila, M., Lenkkeri, U., Mannikko, M., et al. (1998) Positionally cloned gene
for a novel glomerular protein, nephrin, is mutated in congenital nephrotic
syndrome. Mol. Cell 1, 575–582.
[2] Shih, N.Y., Li, S., Karpitskii, V., Nguyen, A., et al. (1999) Congenital nephrotic
syndrome in mice lacking CD2-associated protein. Science 286, 312–315.
[3] Kim, J.M., Wu, H., Green, G., Winkler, C.A., et al. (2003) CD2-associated protein
haploinsufﬁciency is linked to glomerular disease susceptibility. Science 300,
1298–1300.
[4] Löwik, M.M., Groenen, P.J.T.A., Pronk, I., et al. (2007) Focal segmental
glomerulosclerosis in a patient homozygous for a CD2AP mutation. Kidney
Int. 72, 1198–1203.
[5] Kaysen, G.A. (1994) Non renal complications of the nephrotic syndrome. Annu.
Rev. Med. 45, 201–210.
[6] Öqvist, B.W., Rippe, A., Tencer, J. and Rippe, B. (1999) In vivo clearance of
albumin in renal and extrarenal tissues in puromycin aminonucleoside (PAN)
induced nephrotic syndrome. Nephrol. Dial. Transplant. 14, 1898–1903.[7] Koltun, M., Nikolovski, J., Strong, K., et al. (2005) Mechanism of
hypoalbuminemia in rodents. Am. J. Physiol. Heart Circ. Physiol. 288,
H1604–H1610.
[8] Russo, L.M., Sandoval, R.M., Campos, S.B., et al. (2009) Impaired tubular uptake
explains albuminuria in early diabetic nephropathy. J. Am. Soc. Nephrol. 20,
489–494.
[9] Haraldsson, B., Nyström, J. and Deen, W.M. (2008) Properties of the glomerular
barrier and mechanisms of proteinuria. Physiol. Rev. 88, 451–487.
[10] Comper, W.D., Hilliard, L.M., Nikolic-Paterson, D.J. and Russo, L.M. (2008)
Disease-dependent mechanisms of albuminuria. Am. J. Physiol. Renal Physiol.
295, F1589–F1600.
[11] Greive, K.A., Nikolic-Paterson, D.J., Guimarães, M.A.M., et al. (2001) Glomerular
permselectivity factors are not responsible for the increase in fractional
clearance of albumin in rat glomerulonephritis. Am. J. Pathol. 159, 1159–1170.
[12] Osicka, T.M., Pratt, L.M. and Comper, W.D. (1996) Glomerular capillary wall
permeability to albumin and horseradish peroxidase. Nephrology 2, 199–212.
[13] Osicka, T.M. and Comper, W.D. (1997) Protein degradation during renal
passage in normal kidneys is inhibited in experimental albuminuria. Clin. Sci.
93, 65–72.
[14] Hilliard, L.M., Russo, L.M. and Comper, W.D. (2009) Hypertension-mediated
albuminuria is associated with decreased lysosomal activity in the kidney and
heart. Am. J. Nephrol. 29, 454–464.
[15] Peres, G.B., Juliano, M.A., Simöes, M.J. and Michelacci, Y.M. (2013) Lysosomal
enzymes are decreased in the kidney of diabetic rats. Biochim. Biophys. Acta
1832, 85–95.
[16] Hilliard, L.M., Clavant, S.P., Osicka, T.M., et al. (2006) Characterization of the
urinary albumin degradation pathway in the isolated perfused kidney. J. Lab.
Clin. Med. 147, 36–44.
[17] Gudehithlu, K.P., Pegoraro, A.A., Dunea, G., et al. (2004) Degradation of
albumin by the renal proximal tubule cells and the subsequent fate of its
fragments. Kidney Int. 65, 2113–2122.
[18] Ferrell, N., Ricci, K.B., Groszek, J., et al. (2012) Albumin handling by renal
tubular epithelial cells in a microﬂuidic bioreactor. Biotechnol. Bioeng. 109,
797–803.
[19] Slattery, C., Lee, A., Zhang, Y., et al. (2008) In vivo visualization of albumin
degradation in the proximal tubule. Kidney Int. 74, 1480–1486.
[20] Amsellem, S., Gburek, J., Hamard, G., et al. (2010) Cubilin is essential for
albumin reabsorption in the renal proximal tubule. J. Am. Soc. Nephrol. 21,
1859–1867.
[21] Osicka, T.M., Houlihan, C.A., Chan, J.G., et al. (2000) Albuminuria in patients
with type I diabetes is directly linked to changes in the lysosomal-mediated
degradation of albumin during renal passage. Diabetes 49, 1579–1584.
[22] Osicka, T.M., Kiriazis, Z., Pratt, L.M., et al. (2001) Ramipril and aminoguanidine
restore renal lysosomal processing in streptozotocin diabetic rats.
Diabetologia 44, 230–236.
[23] Russo, L.M., Osicka, T.M., Bonnet, F., et al. (2002) Albuminuria in hypertension
is linked to altered lysosomal activity and TGF-1 expression. Hypertension 39,
281–286.
[24] Weyer, K., Nielsen, R., Christensen, E.I. and Birn, H. (2012) Generation of
urinary albumin fragments does not require proximal tubular uptake. J. Am.
Soc. Nephrol. 23, 591–596.
[25] Comper WD: Is there equivalency of intact albuminuria and albumin
peptideuria in nephrotic states? Kidney Int (in press).
[26] Freeman, T. (1959) The biological behaviour of normal and denatured human
plasma albumin. Clin. Chim. Acta 4, 788–792.
[27] Clavant, S.P. and Comper, W.D. (2003) Urinary clearance of albumin is
critically determined by its tertiary structure. J. Lab. Clin. Med. 142, 372–384.
[28] Mego, J.L. (1984) Role of thiols, pH and cathepsin D in the lysosomal
catabolism of serum albumin. Biochem. J. 218, 775–783.
[29] Burne, M.J., Osicka, T.M. and Comper, W.D. (1999) Fractional clearance of high
molecular weight proteins in conscious rats using a continuous infusion
method. Kidney Int. 55, 261–270.
[30] Koltun, M. and Comper, W.D. (2004) Retention of albumin in the circulation is
governed by saturable renal cell-mediated processes. Microcirculation 11,
351–360.
[31] Scandling, J.D., Black, V.M., Deen, W.M. and Myers, B.D. (1992) Glomerular
permselectivity in healthy and nephrotic humans. Adv. Nephrol. Necker Hosp.
21, 159–176.
[32] Mollet, G., Ratelade, Boyer, O., et al. (2009) Podocin inactivation in mature
kidneys causes focal segmental glomerulosclerosis and nephrotic syndrome. J.
Am. Soc. Nephrol. 20, 2181–2189.
[33] Cormont, M., Metón, I., Mari, M., et al. (2003) CD2AP/CMS regulates endosome
morphology and trafﬁc to the degradative pathway through its interaction
with Rab4 and C-Cbl. Trafﬁc 4, 97–112.
